Skip to content
10-Q

Quarterly Report

ENDRA Life Sciences Inc. NDRA

0001213900-26-057680

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 15, 2026 1.27M sh
Shares Diluted Q1 2026 · Mar 31, 2026 1.2M sh
Shares Diluted Q1 2026 · Mar 31, 2025 557.58K sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$1.12M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.29M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.79M
Stockholders Equity Q1 2026 · Dec 31, 2025 $2.26M
Stockholders Equity Q1 2026 · Mar 31, 2025 $1.75M
Stockholders Equity Q1 2026 · Dec 31, 2024 $2.56M
Current Liabilities Q1 2026 · Mar 31, 2026 $835.44K
Current Liabilities Q1 2026 · Dec 31, 2025 $750.96K
Total Liabilities Q1 2026 · Mar 31, 2026 $1.65M
Total Liabilities Q1 2026 · Dec 31, 2025 $1.59M
Current Assets Q1 2026 · Mar 31, 2026 $536.67K
Current Assets Q1 2026 · Dec 31, 2025 $967.97K
Total Assets Q1 2026 · Mar 31, 2026 $3.44M
Total Assets Q1 2026 · Dec 31, 2025 $3.85M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.09
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.86
Eps Basic Q1 2026 · Mar 31, 2026 −$1.09
Eps Basic Q1 2026 · Mar 31, 2025 −$1.86
Sga Expense Q1 2026 · Mar 31, 2026 $1.39M
Sga Expense Q1 2026 · Mar 31, 2025 $871.61K
Rd Expense Q1 2026 · Mar 31, 2026 $776.41K
Rd Expense Q1 2026 · Mar 31, 2025 $528.69K
Net Income Q1 2026 · Mar 31, 2026 −$1.31M
Net Income Q1 2026 · Mar 31, 2025 −$1.04M
Operating Income Q1 2026 · Mar 31, 2026 −$2.17M
Operating Income Q1 2026 · Mar 31, 2025 −$1.47M
Capex Q1 2026 · Mar 31, 2025 $17.28K